Circana added that it believes the industry is at an inflection point in how these drugs, which include Ozempic, Wegovy and Saxenda, will shape spending patterns in the future
That's not a personal failure
Mendes, R., Pedrosa, P., Lima, J
Overall, while GLP-1 RA present several potential risks, the benefit-risk profile remains favorable in most patients when prescribed appropriately
Weight loss: GLP1 analogues cause significantly higher weight loss than previously available weight loss medication This effect was proved in large clinical trials such as STEP, a prospective multi-center randomized controlled trial performed to monitor the semaglutide treatment effect in adults with obesity but without diabetes